BioE Appoints Gayl Rogers Chrysler Vice President of Cellular Technologies and Clinical Affairs.

ST. PAUL, Minn. -- Former National Director of Operations for the National American Red Cross' Cord Blood Program brings unparalleled cord blood expertise to emerging biomedical leader

BioE(R), Inc., a biomedical company providing human cord blood stem cells as enabling, high-quality cellular tools for drug discovery and therapeutic research, announced today it appointed Gayl Rogers Chrysler vice president of cellular technologies and clinical affairs.

Chrysler, former national director of operations for the National American Red Cross' Cord Blood Program, has more than 25 years of unparalleled management experience in the fields of cord blood and blood banking, and tissue and organ procurement. She is considered a noted expert in these fields.

In her role with BioE, Chrysler is responsible for cultivating clinical markets for the company's cell isolation platform -- PrepaCyte(R). The first product derived from this platform, PrepaCyte-CB, is on track to become the first U.S. Food and Drug Administration (FDA)-compliant product for isolating stem cells from human umbilical cord blood. Such a product should serve the cord blood banking industry's need to optimize stem cell processing methods, which in turn may enhance patients' transplant outcomes -- a breakthrough Chrysler confirms is necessary through her work with the American Red Cross.

"It is nothing short of a major coup that we were able to hire someone of Gayl's stature and extensive working knowledge of cord blood and its various uses and storage protocols during a time when the cord blood industry is burgeoning," said Michael Haider, president and chief executive officer for BioE. "There truly is no one better-suited to help us immediately capitalize on numerous growth opportunities involving cord blood and PrepaCyte as we emerge as a leader in the biomedical industry."

"As the need for cord blood as a transplant modality increases, the ability to bank high-quality units for use in transplantation and cellular therapies becomes a critical priority," said Chrysler. "From an outsider's perspective, BioE is making tremendous inroads to address this significant challenge with PrepaCyte-CB, capturing the attention of many people -- including myself while with the American Red Cross. In my new role with the company, I look forward to using my management experience and clinical knowledge to advance the use of PrepaCyte within the cord blood industry and other markets that would benefit from such a powerful medium for selective cell processing. I'm confident our efforts will lead to better patient outcomes, which is BioE's ultimate goal."

Additional Chrysler Background

As national director of operations for the National American Red Cross' Cord Blood Program, Chrysler led the development and implementation of strategies and partnerships with U.S. hospitals and clinics to obtain, match and provide more than 400 cord blood units to transplant centers worldwide for patient transplantation. During her tenure, the American Red Cross maintained one of the nation's top four cord blood banks.

Prior to this role, Chrysler established the American Red Cross' North Central Cord Blood Bank. In this capacity, she developed all operational aspects of creating the regional bank, including partnering with hospitals in offering expectant mothers the option of participation in the program, securing institutional review board (IRB) approval, collecting the cord blood at the time of delivery and assuring proper processing and long-term storage. In addition, Chrysler oversaw the development of a cord blood registry housing more than 8,000 cord blood units for the American Red Cross.

Chrysler also was instrumental in establishing the first federally licensed organ procurement organization (OPO) in the upper Midwest (Minnesota, North Dakota and South Dakota). Furthermore, she helped create the Unrelated Bone Marrow Donor Program for the American Red Cross, which later became the National Marrow Donor Program -- the first program of its kind to recruit unrelated bone marrow donors for patients in need.

Her distinguished work and sought after opinions have been published in numerous journal articles, study abstracts, academic text and news articles. She has presented countless times during industry meetings, conferences and workshops held worldwide. And, since 1991, Chrysler has been an associate editor for Progress in Transplantation, the official journal of the North American Transplant Coordinators Organization. In August 2005, she joined the board of directors for Cord Blood America Inc., an umbilical cord blood stem cell preservation company.

Chrysler holds a master's degree in business administration in health care from the University of St. Thomas, and a bachelor's degree in nursing from the College of St. Catherine; both institutions are located in St. Paul, Minn. She also is a certified/registered nurse.

About BioE

Headquartered in St. Paul, Minn., BioE is a biomedical company providing human cord blood stem cells as enabling, high-quality cellular tools for drug discovery and therapeutic research. The company's novel Multi-Lineage Progenitor Cell(TM) (MLPC(TM)) -- derived from human umbilical cord blood and obtained using PrepaCyte(R), the company's proprietary cell isolation platform -- provides clinicians and researchers a flexible, long-term and non-controversial tool for therapeutic research and drug discovery and screening. BioE is privately owned and was founded in 1993. For more information about the company, please visit www.bioe.com or call [phone].